Notably, ZQJ29 exhibits comparable tumor‐suppressive efficacy to the first‐line clinical chemotherapeutic agent OXA, while exhibiting superior safety profiles characterized by the absence of significant organ toxicity and preserved hepatic function (ALT/AST levels within normal ranges). The gene discussed is GPT; the disease is neoplasm.